b>j)΄!Pԫ&;"kB޶}pSVT(wę!j x;-m@JnQ+պכ7MajfJͱ4jѲ撆RxZMz7vIW/dٞТזcZM~ji ߒsQzԠDW3Den"M+/B:-uIJ7j委9p='mANޭ=/B:-n&nUfqxZM~c Ϲ+,&ᾺܢF[(1*" ϒ"Jԧ<;b" "jܢF[x ,!q қ*]/؝27SMcs"ޭDQ/应ܢF_! :s" 7`F+SVTn"IJnQ/应B 4 wD"IJ׭-`S9DrjiEJ߅gJ应矁[xZM~n"IB؃!'Тѕ+(mIKʭ/|ϐܢF[xZMzG %嬩/c[[ January 22, 2021 – Visionary Ventures
Skip to content
Visionary Ventures
Life sciences venture capital fund investing in ophthalmology and medical aesthetics.
Visionary VenturesVisionary Ventures
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN
Fund Menu
Search
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN

Daily Archives: January 22, 2021

Surface Ophthalmics Announces Positive Top-Line Phase II Results

News, SurfaceBy Garrett HamontreeJanuary 22, 2021

Surface Ophthalmics Announces Positive Top-Line Results from Phase II Trial for SURF-201 (Betamethasone 0.2% in Klarity® vehicle) for the Treatment of Post-Cataract Surgery Pain and Inflammation. Investigational therapy SURF-201 met all primary endpoints for the treatment of pain and inflammation following cataract surgery.

  • Home
  • Ophthalmology
  • Team
    • Investment Committee
    • Visionary KOLs
    • Fund Management
  • Portfolio
  • News
  • Contact
  • Investor Portal
Footer Menu

© 2019 Visionary Ventures. All Rights Reserved.

Go to Top